NASDAQ:IFRX
InflaRx N.V. Stock News
$1.18
-0.0200 (-1.67%)
At Close: May 10, 2024
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07:30am, Thursday, 09'th Sep 2021
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, annou
IFRX Stock: Over 9% Increase Pre-Market Explanation
09:11am, Wednesday, 08'th Sep 2021
The stock price of Inflarx NV (NASDAQ: IFRX) increased by over 9% pre-market. This is why it happened.
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
07:30am, Wednesday, 08'th Sep 2021
JENA, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
01:54pm, Wednesday, 25'th Aug 2021
Most are asking is an investment in InflaRx worth it? Presumably, this question is in response to the FDA regulatory hurdle currently playing out with the NDA for avacopan by ChemoCentryx.
JENA, Germany, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a
InflaRx to Present at the BTIG Virtual Biotechnology Conference
07:30am, Friday, 06'th Aug 2021
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will p
InflaRx to Present at the Raymond James Human Health Innovation Conference
07:30am, Thursday, 17'th Jun 2021
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, w
A Trio of Net Current Asset Value Stock Picks
12:07pm, Wednesday, 09'th Jun 2021
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
07:30am, Tuesday, 08'th Jun 2021
JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, t
Tony Gibney Joins InflaRx Board of Directors
07:30am, Friday, 21'st May 2021
JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, to
InflaRx Reports First Quarter 2021 Financial & Operating Results
07:30am, Wednesday, 12'th May 2021
JENA, Germany, May 12, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc
InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study
07:15am, Wednesday, 12'th May 2021
InflaRx NV (NASDAQ: IFRX) has announced topline results from its U.S. Phase 2 IXPLORE study evaluating vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated va
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
04:30pm, Tuesday, 11'th May 2021
JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc
InflaRx Reports Full Year 2020 Financial & Operating Results
06:30am, Thursday, 25'th Mar 2021
JENA, Germany, March 25, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, annou
InflaRx to Present at Upcoming Investor Conferences
07:30am, Wednesday, 03'rd Mar 2021
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at tw
